Original Query: ALL
Previous Study | Return to List | Next Study

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01779791
Recruitment Status : Completed
First Posted : January 30, 2013
Last Update Posted : July 18, 2017
Pharmacyclics LLC.
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : May 18, 2016
  Study Completion Date : May 18, 2016